Amgen Inc (AMGN) operating KPIs

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value

$466.01+5.28 (+1.15%)

Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%

Amgen gAAP Operating Margin as % of Product Sales (%) (%)

Form 8-K Reconciliations of GAAP to Non-GAAP Measures

Quarterly Annual

Latest, FY2025

25.8%

Period ended Dec 31, 2025

Change on a year earlier

+3.1 pts

22.7% in FY2024

History

9 years

Since FY2017

Sources

Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	GAAP Operating Margin as % of Product Sales (%) (%)	Year on year	Source
FY2025	Dec 31, 2025	25.8%	+3.1 pts	Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
FY2024	Dec 31, 2024	22.7%	-6.6 pts	Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗
FY2023	Dec 31, 2023	29.3%	-9.3 pts	Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗
FY2022	Dec 31, 2022	38.6%	+7.2 pts	Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗
FY2021	Dec 31, 2021	31.4%	-6.3 pts	Form 8-K (amgenq42021earningsrelease.htm, filed 2022-02-07) ↗
FY2020	Dec 31, 2020	37.7%	-5.9 pts	Form 8-K (amgn-20201231xq4ex991.htm, filed 2021-02-02) ↗
FY2019	Dec 31, 2019	43.6%	-1.9 pts	Form 8-K (amgn-20191231xq4ex991.htm, filed 2020-01-30) ↗
FY2018	Dec 31, 2018	45.5%	-0.3 pts	Form 8-K (amgn-20181231xq4exhibit991.htm, filed 2019-01-29) ↗
FY2017	Dec 31, 2017	45.8%	–	Form 8-K (amgn-20181231xq4exhibit991.htm, filed 2019-01-29) ↗

Cite this data

StockData. (2026). Amgen GAAP Operating Margin as % of Product Sales (%) (%), annual FY2017–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/gaap_op_margin

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.